Sugi Predict

Sugi Predict / Targets / PAICS

PAICS

Bifunctional phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase · P22234 · PAICS on Sugi Atlas →

3,375 patent compounds predicted against PAICS, 1,932 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL20338894 SCHEMBL20338894 1.00 20/20
SCHEMBL20338896 SCHEMBL20338896 1.00 20/20
SCHEMBL20338897 SCHEMBL20338897 1.00 20/20
SCHEMBL20338899 SCHEMBL20338899 1.00 20/20
SCHEMBL20338903 SCHEMBL20338903 1.00 20/20
SCHEMBL20338910 SCHEMBL20338910 1.00 20/20
SCHEMBL20338911 SCHEMBL20338911 1.00 20/20
SCHEMBL20338913 SCHEMBL20338913 1.00 20/20
SCHEMBL20338917 SCHEMBL20338917 1.00 20/20
SCHEMBL20338920 SCHEMBL20338920 1.00 20/20
SCHEMBL20338935 SCHEMBL20338935 1.00 20/20
SCHEMBL20338938 SCHEMBL20338938 1.00 20/20
SCHEMBL20338954 SCHEMBL20338954 1.00 20/20
SCHEMBL20338955 SCHEMBL20338955 1.00 20/20
SCHEMBL20338968 SCHEMBL20338968 1.00 20/20
SCHEMBL20338965 SCHEMBL20338965 0.90 20/20
SCHEMBL20338960 SCHEMBL20338960 0.83 20/20
SCHEMBL20338919 SCHEMBL20338919 0.77 20/20
SCHEMBL20338918 SCHEMBL20338918 0.75 20/20
SCHEMBL20338890 SCHEMBL20338890 0.75 20/20

Clinical trials — most relevant to PAICS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PSMA/CD70 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma PHASE2NOT_YET_RECRUITING
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL PHASE1/PHASE2RECRUITING
GD2/PSMA Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
GD2/CD56 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol PHASE2RECRUITING
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
CD19/22 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL PHASE1/PHASE2RECRUITING
GD2/CD70 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC PHASE1/PHASE2UNKNOWN
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). PHASE1/PHASE2RECRUITING
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies PHASE2COMPLETED
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies PHASE1COMPLETED
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies PHASE1ACTIVE_NOT_RECRUITING
Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy PHASE1NOT_YET_RECRUITING
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma PHASE1WITHDRAWN
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia PHASE1RECRUITING
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia PHASE1RECRUITING
Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy PHASE1COMPLETED
Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study PHASE1RECRUITING
Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients PHASE1UNKNOWN
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia PHASE1ACTIVE_NOT_RECRUITING
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial PHASE1SUSPENDED
A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors EARLY_PHASE1NOT_YET_RECRUITING
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia EARLY_PHASE1UNKNOWN
Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders EARLY_PHASE1NOT_YET_RECRUITING
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors EARLY_PHASE1NOT_YET_RECRUITING
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research EARLY_PHASE1RECRUITING
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PAICS binder may also engage these)

ProteinNameSimilarity
Q5RB59 — 1.000 Q5RB59 →
P51583 — 0.998 P51583 →
Q9DCL9 — 0.990 Q9DCL9 →
P38024 — 0.970 P38024 →
Q6P1K8 — 0.957 Q6P1K8 →
Q13888 — 0.956 Q13888 →
Q2TBV5 — 0.955 Q2TBV5 →
Q9JIB4 — 0.954 Q9JIB4 →
A0JN27 — 0.952 A0JN27 →
Q4R9A8 — 0.949 Q4R9A8 →
Q5R532 — 0.947 Q5R532 →
Q5F398 — 0.947 Q5F398 →
Q4VC33 — 0.946 Q4VC33 →
Q7L5Y9 — 0.946 Q7L5Y9 →
Q7SXR3 — 0.945 Q7SXR3 →
Q8R3T5 — 0.944 Q8R3T5 →
Q6GR10 — 0.944 Q6GR10 →
Q2YDL1 — 0.944 Q2YDL1 →
Q5ZJQ7 — 0.943 Q5ZJQ7 →
Q5RKJ1 — 0.942 Q5RKJ1 →
GLS Glutaminase kidney isoform, mitochondrial 0.942 landscape →
Q9H9T3 — 0.942 Q9H9T3 →
CDC16 Cell division cycle protein 16 homolog 0.941 landscape →
Q67FW5 — 0.941 Q67FW5 →
Q17QI2 — 0.941 Q17QI2 →
Q3MHJ2 — 0.940 Q3MHJ2 →
A1L167 — 0.940 A1L167 →
Q5HZM6 — 0.940 Q5HZM6 →
Q8BWB6 — 0.940 Q8BWB6 →
Q5NVN7 — 0.939 Q5NVN7 →